Annals of Clinical and Translational Neurology

Article	Citations
Persistent neurologic symptoms and cognitive dysfunction in non‐hospitalized Covid‐19 “long haulers”	409
Frequent neurologic manifestations and encephalopathy‐associated morbidity in Covid‐19 patients	341
Blood neurofilament light: a critical review of its application to neurologic disease	128
DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and France	86
Anakinra usage in febrile infection related epilepsy syndrome: an international cohort	79
Repeat expansion scanning of the NOTCH2NLC gene in patients with multiple system atrophy	67
Long COVID‐19: Objectifying most self‐reported neurological symptoms	65
Longitudinal biomarkers in amyotrophic lateral sclerosis	62
De Novo Status Epilepticus in patients with COVID‐19	59
Serious safety events in rituximab‐treated multiple sclerosis and related disorders	57
Neurological manifestations of coronavirus infections – a systematic review	56
Natural history of Type 2 and 3 spinal muscular atrophy: 2‐year NatHis‐SMA study	55
Gut microbiome variation is associated to Multiple Sclerosis phenotypic subtypes	54
Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID‐19	51
Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1/2 study	51
Seizures and risk of epilepsy in anti‐NMDAR, anti‐LGI1, and anti‐GABABR encephalitis	49
Brain dysfunction in COVID‐19 and CAR‐T therapy: cytokine storm‐associated encephalopathy	49
Retraining and control therapy for pediatric psychogenic non‐epileptic seizures	49
Improved ALS clinical trials through frequent at‐home self‐assessment: a proof of concept study	48
230 days of ultra long‐term subcutaneous EEG: seizure cycle analysis and comparison to patient diary	46
Insular and occipital changes in visual snow syndrome: a BOLD fMRI and MRS study	45
Cortical hyperexcitability evolves with disease progression in ALS	44
Comparison of SimoaTM and EllaTM to assess serum neurofilament‐light chain in multiple sclerosis	44
Centromedian thalamic responsive neurostimulation for Lennox‐Gastaut epilepsy and autism	43
Experiences of telemedicine in neurological out‐patient clinics during the COVID‐19 pandemic	43

Diaphragm dysfunction in severe COVID‐19 as determined by neuromuscular ultrasound	42
Detection of prions in skin punch biopsies of Creutzfeldt–Jakob disease patients	42
Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease	41
Role of homocysteine in the development and progression of Parkinson’s disease	41
The A4 study: β‐amyloid and cognition in 4432 cognitively unimpaired adults	39
A rapid α‐synuclein seed assay of Parkinson’s disease CSF panel shows high diagnostic accuracy	39
Long‐term peripheral immune cell profiling reveals further targets of oral cladribine in MS	39
Neuronal intranuclear inclusion disease is genetically heterogeneous	38
Evolution of neurologic symptoms in non‐hospitalized COVID‐19 “long haulers”	38
Dopamine transporter imaging predicts clinically‐defined α‐synucleinopathy in REM sleep behavior disorder	37
Acute disseminated encephalomyelitis in a patient vaccinated against SARS‐CoV‐2	36
Developmental regression and mitochondrial function in children with autism	36
Re‐defining the clinicopathological spectrum of neuronal intranuclear inclusion disease	36
The brain–heart interaction in epilepsy: implications for diagnosis, therapy, and SUDEP prevention	36
Optical coherence tomography in multiple sclerosis: A 3‐year prospective multicenter study	35
QSM is an imaging biomarker for chronic glial activation in multiple sclerosis lesions	35
Spreading in ALS: The relative impact of upper and lower motor neuron involvement	34
Type I SMA “new natural history”: long‐term data in nusinersen‐treated patients	34
Validation of differentially expressed brain‐enriched microRNAs in the plasma of PD patients	34
Temporal association of sNfL and gad‐enhancing lesions in multiple sclerosis	34
Prolonged confusional state as first manifestation of COVID‐19	33
Spinocerebellar ataxia clinical trials: opportunities and challenges	33
Genetic modifiers of respiratory function in Duchenne muscular dystrophy	32
Cerebellar cognitive disorder parallels cerebellar motor symptoms in Friedreich ataxia	32
The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes	32
Automated cot‐side tracking of functional brain age in preterm infants	32
Deep learning with diffusion basis spectrum imaging for classification of multiple sclerosis lesions	31
Interictal spike networks predict surgical outcome in patients with drug‐resistant focal epilepsy	31
Obesity and the risk of Multiple Sclerosis. The role of Leptin	31
Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy	30
Elevated matrix metalloproteinase‐9 levels in neuronal extracellular vesicles in Alzheimer’s disease	30
Early life metal dysregulation in amyotrophic lateral sclerosis	29
Walking in multiple sclerosis improves with tDCS: a randomized, double‐blind, sham‐controlled study	29
Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children	29
Artificial intelligence extension of the OSCAR‐IB criteria	29
Intrathecal dexamethasone therapy for febrile infection‐related epilepsy syndrome	28
FGF14‐related episodic ataxia: delineating the phenotype of Episodic Ataxia type 9	28
Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment	28
Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy	27
Plasma lipid metabolites associate with diabetic polyneuropathy in a cohort with type 2 diabetes	27
11C‐PK11195 PET–based molecular study of microglia activation in SOD1 amyotrophic lateral sclerosis	27
Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma	27
Targeted gene panel use in 2249 neuromuscular patients: the Australasian referral center experience	27
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy	27
Synaptic density in carriers of C9orf72 mutations: a [11C]UCB‐J PET study	27
Parkinson disease clinical subtypes: key features & clinical milestones	27
Isradipine plasma pharmacokinetics and exposure–response in early Parkinson’s disease	26
Ring trial of 2nd generation RT‐QuIC diagnostic tests for sporadic CJD	26
Multiple sclerosis, rituximab, and COVID‐19	26
CSF chitinases before and after symptom onset in amyotrophic lateral sclerosis	26

Comparing progression biomarkers in clinical trials of early Alzheimer’s disease	26
Adeno‐associated virus serotype 1‐based gene therapy for FTD caused by GRN mutations	25
LAMA2‐related muscular dystrophy: Natural history of a large pediatric cohort	25
Neuronal RNA‐binding protein dysfunction in multiple sclerosis cortex	25
Clinical efficacy of plasma exchange in patients with autoimmune encephalitis	24
Vocal music enhances memory and language recovery after stroke: pooled results from two RCTs	24
Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases	24
Ratio and index of Neurofilament light chain indicate its origin in Guillain‐Barré Syndrome	24
Remote ischemic conditioning combined with intravenous thrombolysis for acute ischemic stroke	24
Gradient of brain mosaic RHEB variants causes a continuum of cortical dysplasia	24
Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease	23
Levels of brain‐derived neurotrophic factor in patients with multiple sclerosis	23
Idebenone increases chance of stabilization/recovery of visual acuity in OPA1‐dominant optic atrophy	23
HLA‐B27 association of autoimmune encephalitis induced by PD‐L1 inhibitor	23
Longitudinal Measurements of Glucocerebrosidase activity in Parkinson’s patients	23
Is autism driven by epilepsy in infants with Tuberous Sclerosis Complex?	23
Delta power robustly predicts cognitive function in Angelman syndrome	23
Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population	23
Prevalence and patterns of symptoms of dysautonomia in patients with long‐COVID syndrome: A cross‐sectional study	23
Choroid plexus volume in multiple sclerosis predicts expansion of chronic lesions and brain atrophy	22
Ataluren for drug‐resistant epilepsy in nonsense variant‐mediated Dravet syndrome and CDKL5 deficiency disorder	22
Neurological manifestations of Erdheim–Chester Disease	22
Mortality of neuromyelitis optica spectrum disorders in a Chinese population	22
Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: A systematic review	22
Mendelian etiologies identified with whole exome sequencing in cerebral palsy	22
Long‐term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses	22
Quantifying regional α ‐synuclein, amyloid β, and tau accumulation in lewy body dementia	21
Prognosis and risk factors for reocclusion after mechanical thrombectomy	21
Long‐read whole‐genome sequencing for the genetic diagnosis of dystrophinopathies	21
Nusinersen efficacy data for 24‐month in type 2 and 3 spinal muscular atrophy	21
Gut microbiome is associated with multiple sclerosis activity in children	21
Trait impulsivity in Juvenile Myoclonic Epilepsy	21
Brain volumetric deficits in MAPT mutation carriers: a multisite study	21
Transmission of CJD from nasal brushings but not spinal fluid or RT‐QuIC product	21
Hereditary transthyretin amyloidosis in mainland China: a unicentric retrospective study	21
Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment	21
Longitudinal evaluation of neurologic‐post acute sequelae SARS‐CoV‐2 infection symptoms	21
Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis	20
Impaired proteasome activity and neurodegeneration with brain iron accumulation in FBXO7 defect	20
Genetic factors for susceptibility to and manifestations of neuromyelitis optica	20
Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis	20
Mechanistic underpinning of an inside–out concept for autoimmunity in multiple sclerosis	20
A Phase 1 study of GDC‐0134, a dual leucine zipper kinase inhibitor, in ALS	20
Multiple sclerosis and inflammatory bowel disease: A systematic review and meta‐analysis	20
Age‐ and disease‐specific reference values for neurofilament light presented in an online interactive support interface	19
Subcortical short‐term plasticity elicited by deep brain stimulation	19
White matter and neurite morphology differ in psychogenic nonepileptic seizures	19
Inflammatory pathway analytes predicting rapid cognitive decline in MCI stage of Alzheimer’s disease	19
Association of rare variants in neurodegenerative genes with familial Alzheimer’s disease	19
Manifestations and impact of the COVID‐19 pandemic in neuroinflammatory diseases	19
KCNQ2‐DEE: developmental or epileptic encephalopathy?	19
Motor beta cortical oscillations are related with the gait kinematics of youth with cerebral palsy	19
Multi‐cohort profiling reveals elevated CSF levels of brain‐enriched proteins in Alzheimer’s disease	19
A meta‐analysis comparing first‐line immunosuppressants in neuromyelitis optica	19
Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy	19
Impaired cerebral autoregulation is associated with poststroke cognitive impairment	19
CSF parvalbumin levels reflect interneuron loss linked with cortical pathology in multiple sclerosis	19
Development of an age‐adjusted model for blood neurofilament light chain	19
Comparison of plasma and CSF biomarkers in predicting cognitive decline	18
Global FKRP Registry: observations in more than 300 patients with Limb Girdle Muscular Dystrophy R9	18
Clinical utility of anti‐cytosolic 5’‐nucleotidase 1A antibody in idiopathic inflammatory myopathies	18
The influence of white matter hyperintensity on cognitive impairment in Parkinson's disease	18
Vorinostat in the acute neuroinflammatory form of X‐linked adrenoleukodystrophy	18
Design of a virtual longitudinal observational study in Parkinson’s disease (AT‐HOME PD)	18
A recurrent PJA1 variant in trigonocephaly and neurodevelopmental disorders	18
An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy	18
Effect of diabetes control status on the progression of Parkinson’s disease: A prospective study	18
Impaired phonemic discrimination in logopenic variant primary progressive aphasia	18
Selenoprotein N‐related myopathy: a retrospective natural history study to guide clinical trials	17
Resection of piriform cortex predicts seizure freedom in temporal lobe epilepsy	17
Habitual sleep disturbances and migraine: a Mendelian randomization study	17
Cognitive reserve and midlife vascular risk: Cognitive and clinical outcomes	17
Demographic characteristics and neuropsychological assessments of subjective cognitive decline (SCD) (plus)	17
Serum neurofilament light chain in FTLD: association with C9orf72, clinical phenotype, and prognosis	17
Prognostic value of serum/plasma neurofilament light chain for COVID‐19‐associated mortality	17
Reversing 21 years of chronic paralysis via non‐invasive spinal cord neuromodulation: a case study	17
Recurrent seizure‐related GRIN1 variant: Molecular mechanism and targeted therapy	17
Relation of plasma β‐amyloid, clusterin, and tau with cerebral microbleeds: Framingham Heart Study	17
Tau pathology associates with in vivo cortical thinning in Lewy body disorders	17
Leveraging electronic health records data to predict multiple sclerosis disease activity	17

Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study	17
Postoperative changes in cognition and cerebrospinal fluid neurodegenerative disease biomarkers	17
TDP‐43 as structure‐based biomarker in amyotrophic lateral sclerosis	17
GGC repeat expansions in NOTCH2NLC causing a phenotype of distal motor neuropathy and myopathy	17
Acute epileptiform abnormalities are the primary predictors of post‐stroke epilepsy: a matched, case–control study	16
MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous	16
A meta‐analysis of the global impact of the COVID‐19 pandemic on stroke care & the Houston Experience	16
Sustained immunotolerance in multiple sclerosis after stem cell transplant	16
Cardioselective peripheral noradrenergic deficiency in Lewy body synucleinopathies	16
Mutated RAP1GDS1 causes a new syndrome of dysmorphic feature, intellectual disability & speech delay	16
Accuracy of FGF‐21 and GDF‐15 for the diagnosis of mitochondrial disorders: A meta‐analysis	16
SARS‐COV‐2 a trigger of myelin oligodendrocyte glycoprotein‐associated disorder	16
GYS1 or PPP1R3C deficiency rescues murine adult polyglucosan body disease	16
Hematoma enlargement characteristics in deep versus lobar intracerebral hemorrhage	16
aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis	16
Lipid levels and the risk of dementia: A dose–response meta‐analysis of prospective cohort studies	16
Immune responses to SARS‐CoV‐2 vaccination in multiple sclerosis: a systematic review/meta‐analysis	15
Genetic prediction of impulse control disorders in Parkinson's disease	15
Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis	15
Safety and efficacy of unilateral and bilateral pallidotomy for primary dystonia	15
Whole‐exome and HLA sequencing in Febrile infection‐related epilepsy syndrome	15
Evolution of white matter damage in amyotrophic lateral sclerosis	15
Neuroprotective effects of FK866 against traumatic brain injury: Involvement of p38/ERK pathway	15
Consistent improvement with eculizumab across muscle groups in myasthenia gravis	15
UCHL1 from serum and CSF is a candidate biomarker for amyotrophic lateral sclerosis	15
Amyloid‐β PET and CSF in an autopsy‐confirmed cohort	15
Altered coupling between resting‐state glucose metabolism and functional activity in epilepsy	15
Hippocampal sclerosis, TDP‐43, and the duration of the symptoms of dementia of AD patients	15
Effect of plasma exchange in neuromyelitis optica spectrum disorder: A systematic review and meta‐analysis	15
Loss of ap4s1 in zebrafish leads to neurodevelopmental defects resembling spastic paraplegia 52	15
Machine learning prediction of the adverse outcome for nontraumatic subarachnoid hemorrhage patients	14
Central nervous system vascular malformations: A clinical review	14
Dynamics of pseudo‐atrophy in RRMS reveals predominant gray matter compartmentalization	14
Neurodegeneration trajectory in pediatric and adult/late DM1: A follow‐up MRI study across a decade	14
Association between amphetamine‐related disorders and dementia‐a nationwide cohort study in Taiwan	14
Assessing the role of rare genetic variants in drug‐resistant, non‐lesional focal epilepsy	14
Younger age of stroke in low‐middle income countries is related to healthcare access and quality	14
In‐depth peripheral CD4+ T profile correlates with myasthenic crisis	14
Baseline characteristics of the North American prodromal Synucleinopathy cohort	14
Intravenous arylsulfatase A in metachromatic leukodystrophy: a phase 1/2 study	14
Lack of progression of beta dynamics after long‐term subthalamic neurostimulation	14
Neuronal intermediate filament IgGs in CSF: Autoimmune Axonopathy Biomarkers	13
Evaluation of SORD mutations as a novel cause of Charcot‐Marie‐Tooth disease	13
Cognitive impairment in patients with Neuro‐Sjögren	13
Heritability of alpha and sensorimotor network changes in temporal lobe epilepsy	13
Congenital myasthenic syndrome in China: genetic and myopathological characterization	13
Early‐onset Alzheimer's disease shows a distinct neuropsychological profile and more aggressive trajectories of cognitive decline than late‐onset	13
Optic, trigeminal, and facial neuropathy related to anti‐neurofascin 155 antibody	13
Effects of PB‐TURSO on the transcriptional and metabolic landscape of sporadic ALS fibroblasts	13
Biallelic GRM7 variants cause epilepsy, microcephaly, and cerebral atrophy	13
Ocular ultrasonography to detect intracranial pressure in aneurysmal subarachnoid hemorrhage	13
Spinocerebellar ataxia type 14: refining clinicogenetic diagnosis in a rare adult‐onset disorder	13
Sirolimus for epileptic seizures associated with focal cortical dysplasia type II	13
Functional and pharmacological evaluation of a novel SCN2A variant linked to early‐onset epilepsy	12
Dopamine D1 + D3 receptor density may correlate with parkinson disease clinical features	12
No strong HLA association with MOG antibody disease in the UK population	12
Novel SPTBN2 gene mutation and first intragenic deletion in early onset spinocerebellar ataxia type 5	12
Expansion of the genetic landscape of ERLIN2‐related disorders	12
Factors influencing the acute pentylenetetrazole‐induced seizure paradigm and a literature review	12
Plasma calcitonin gene‐related peptide (CGRP) in migraine and endometriosis during the menstrual cycle	12
Association of serum Apolipoprotein B with cerebrospinal fluid biomarkers of Alzheimer’s pathology	12
Systematic review of CMTX1 patients with episodic neurological dysfunction	12
Abolishing spontaneous epileptiform activity in human brain tissue through AMPA receptor inhibition	12
Home‐based biofeedback speech treatment improves dysarthria in repeat‐expansion SCAs	12
CD8+ T cell subpopulations and pro‐inflammatory cytokines in neuromyelitis optica spectrum disorder	12
Anakinra treatment for refractory cerebral autoinflammatory responses	12
Serum lipidomic determinants of human diabetic neuropathy in type 2 diabetes	12
Predictors of cognitive decline in older individuals without dementia: An updated meta‐analysis	12
Functional dystonia: A case‐control study and risk prediction algorithm	12
Electrophysiological properties and seizure networks in hypothalamic hamartoma	12
Predictors of worsening neuropathy and neuropathic pain after 12 years in people with HIV	12
Clinical characteristics of Taiwanese patients with Hereditary spastic paraplegia type 5	12
Drug‐refractory myasthenia gravis: Clinical characteristics, treatments, and outcome	12
Test–retest reliability of the Friedreich’s ataxia rating scale	12
Initial findings in traumatic peripheral nerve injury and repair with diffusion tensor imaging	11
The safety and efficacy of intravenous immunoglobulin in autoimmune encephalitis	11
Excitatory and inhibitory neuron defects in a mouse model of Scn1b‐linked EIEE52	11
Genetic variation contributes to gene expression response in ischemic stroke: an eQTL study	11
Phospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease	11
Long‐term continuation of anti‐seizure medications after acute stroke	11
Swallowing‐related neural oscillation: an intracranial EEG study	11
Using urine to diagnose large‐scale mtDNA deletions in adult patients	11
Physical activity level and stroke risk in US population: A matched case–control study of 102,578 individuals	11
Evaluation of peripherin in biofluids of patients with motor neuron diseases	11
Vitamin D concentration and focal brain atrophy in older adults: a voxel‐based morphometric study	11
Correlation of plasma and neuroimaging biomarkers in Alzheimer's disease	11
Peripheral synucleinopathy in Parkinson disease with LRRK2 G2385R variants	11
Reliability and accuracy of EEG interpretation for estimating age in preterm infants	11
Cardiac arrhythmias in Dravet syndrome: an observational multicenter study	11
Genetic spectrum in a cohort of patients with distal hereditary motor neuropathy	11
Expanding the clinical and genetic heterogeneity of SPAX5	11
Characteristics and outcome of facial nerve palsy from Lyme neuroborreliosis in the United States	11
Decreased serum creatinine levels predict short survival in amyotrophic lateral sclerosis	11
Expanding the phenotypic spectrum of BCS1L‐related mitochondrial disease	11
The CSF Levels of Neutrophil‐Related Chemokines in Patients with Neuromyelitis Optica	11